Provided by Tiger Trade Technology Pte. Ltd.

CSTONE PHARMA-B

5.695
-0.055-0.96%
Volume:1.58M
Turnover:8.99M
Market Cap:9.09B
PE:-18.09
High:5.790
Open:5.750
Low:5.600
Close:5.750
52wk High:13.150
52wk Low:4.010
Shares:1.60B
HK Float Shares:1.60B
Volume Ratio:0.47
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.315
ROE:-52.14%
ROA:-14.44%
PB:6.03
PE(LYR):-18.09
PS:18.33

Loading ...

Key Biotech Stock Surges in Late Trading on Clinical Trial Progress and Insider Buying

Stock News
·
Jun 12

CStone says CS2009 posts 81.3% ORR in first-line PD-L1-high NSCLC Phase I study at ASCO 2026

Reuters
·
Jun 12

CStone Pharmaceuticals Drug Receives Ethics Approval in Australia

MT Newswires Live
·
Jun 12

Directors' Major Share Purchases Signal Confidence in Drug Developer's Long-Term Prospects

Stock News
·
Jun 12

CStone Pharma-B Launches Global Phase I Trial for Key ADC Candidate CS5007

Stock News
·
Jun 12

CStone says CS5007 Phase I trial wins Australian ethics approval

Reuters
·
Jun 12

CStone says Phase I data show CS2009 trispecific antibody posts 24% ORR in later-line NSCLC

Reuters
·
Jun 11

Insider Transaction: CEO Yang Jianshu Purchases Additional Shares in CStone Pharmaceuticals

Stock News
·
Jun 10

CStone Pharmaceuticals CEO, President of R&D and Executive Director Acquires 1.0% More Stock

Simply Wall St.
·
Jun 07

AKESO's New Drug Achieves Historic Milestone, Yet Market Cap Plummets by Tens of Billions

Deep News
·
Jun 05

Jefferies Maintains Buy Rating on CStone Pharma, Citing Management Confidence and Promising CS2009 Data

Stock News
·
Jun 04

CStone Pharmaceuticals Says CEO, Directors, Senior Management Initiate Joint Share Purchase Plan

Reuters
·
Jun 03

Key Executives and Board Members of CStone Pharmaceuticals to Purchase Additional Company Shares

Stock News
·
Jun 03

CStone Pharmaceuticals - CEO, Directors, and Senior Management Initiate Joint Share Purchase Plan

THOMSON REUTERS
·
Jun 03

CStone Pharmaceuticals - Share Purchases to Total 2 Mln to 5 Mln Shares From June 2026

THOMSON REUTERS
·
Jun 03

Goldman Sachs Issues Post-ASCO Analysis, Reiterates Buy Rating on CStone with HK$9.44 Target

Stock News
·
Jun 02

CStone Pharmaceuticals Sets 23 June 2026 AGM; Seeks Approval for Director Re-election, 20% Issuance Mandate and Equity Awards to CEO

Bulletin Express
·
Jun 01

CStone Pharma to Seek Shareholder Nod for 20% Issue Mandate, 10% Buy-Back Capacity and CEO Equity Awards

Bulletin Express
·
Jun 01

CStone: ASCO 2026 Data Underscore Robust Efficacy and Safety of Trispecific Antibody CS2009; Phase III Global Trial Planned for Year-End

Bulletin Express
·
Jun 01

CStone presents ASCO data for CS2009 PD-1/VEGF/CTLA-4 trispecific antibody in lung, colorectal cancer trials

Reuters
·
Jun 01